Pharma: Other News To Note
Wednesday, October 9, 2013
• Medivir AB, of Stockholm, Sweden, said Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, acquired investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in Phase II development of chronic hepatitis C virus (HCV) from an affiliate of London-based Glaxosmithkline plc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.